Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of subcutaneous netakimab in Chinese adults with active ankylosing spondylitis
CTR20222555Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of netakimab in ankylosing spondylitis (AS), sponsored by BIOCAD. Started Mar 2023; status: completed.
02
Drugs
netakimab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20222555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222555.